A Phase II Trial of Pembrolizumab as Standard of Care + sEphB4-HSA in Chemotherapy Ineligible or Chemotherapy Refusing Patients With Metastatic Urothelial Carcinoma
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Pembrolizumab (Primary) ; SEphB4-HSA (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Sponsors VasGene Therapeutics
- 19 Aug 2020 Planned Initiation Date ( Date of recruitment of first participant) is 31 Dec 2020.
- 19 Aug 2020 Status changed from not yet recruiting to recruiting.
- 30 Jul 2020 New trial record